Global IgA Nephropathy Market to Reach USD 85 Billion by 2033, Growing at a CAGR of 7.5%

IgA Nephropathy Market

The global IgA nephropathy market is set to experience significant growth over the next decade, with the market expected to be valued at USD 41.24 billion in 2023. According to a new report, the market is projected to expand at a Compound Annual Growth Rate (CAGR) of 7.5%, reaching a valuation of USD 85 billion by 2033.

The rising prevalence of kidney diseases across various age groups is a key driver of the IgA nephropathy market. The market experienced a CAGR of 4.8% during the historical period from 2017 to 2022 and is now on a faster growth trajectory. IgA nephropathy (IgAN) is an autoimmune disorder that primarily affects the kidneys, leading to impaired blood filtration in the small vessels of the organ. The disease occurs when an abnormal protein damages the kidney’s filtering unit, the glomerulus, resulting in pain and the need for various treatment options.

With an increasing global burden of kidney diseases and advancements in treatment approaches, the market for IgA nephropathy is expected to continue its robust growth, providing new opportunities for therapeutic development.

The COVID-19 pandemic has been associated with increase in hospitalization and infection hotspots around the country. There were at least three separate waves of COVID-19 around the world by June 2021 that put a significant strain on hospital resources, especially labor and availability of dialysis equipment & supplies. In addition, the COVID-19 pandemic has affected healthcare services for renal disease patients. Social distancing and lockdown were mandate norms, globally, leading to temporary closure of other medical services. The diagnosis of several renal diseases deferred during the pandemic due to suspension of non-urgent visits and testing services.

On the other hand, increasing awareness regarding IgA nephropathy is expected to create lucrative opportunities for the market growth. For instance, In the U.S., an estimated 37 million adults have kidney disease. Major risk factors for the disease are high blood pressure and diabetes as well as heart disease, obesity, & family history of kidney disease. In addition, North America and Asia Pacific are two major regions contributing to the IgA nephropathy market.

Key Takeaways from the Market Study

• IgA Nephropathy market to garner US$ 85 Billion by the end of 2033.
• IgA Nephropathy market to register a positive CAGR of 7.5% in the forecast period 2023-2033
• By end user, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
• By diagnosis, the urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years.
• North America is expected to possess 40% market share for IgA nephropathy market in 2023.
• Asia Pacific is expected to hold 35% market share for IgA nephropathy market share in 2023.

“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA nephropathy market” states a FMI analyst

Competitive Landscape

Some of the key companies in the IgA Nephropathy market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others

· In June 2021, Novartis Pharmaceuticals announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN).

• Chinook Therapeutics, Inc, a key player in the IgA nephropathy market is focusing on diagnosing the causes of the ailment and offering customized and specific treatments based on the same.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global IgA nephropathy market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Diagnosis (Iothalamate Clearance Test, Kidney Biopsy, Blood Tests, Urine Tests) Diseases Type( Primary IgA Nephropathy, Secondary IgA Nephropathy), Systems(Hematuria, Proteinuria, Edema, Others), Population Type (Pediatrics, Adults), Route of Administration (Oral, Parenteral, Others), Treatment (Medication, Statin therapy, Omega-3 fatty acids, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin receptor blockers (ARBs), Diuretics, Immunosuppressants, Kidney Transplantation, Others), End Users (Hospitals, Specialty Clinics, Homecare, Others) regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

A Full Report Overview

Key Segments Profiled in the IgA Nephropathy Market Survey

Diagnosis:

• Iothalamate Clearance Test
• Kidney Biopsy
• Blood Tests
• Urine Tests

Diseases Type:

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

Systems:

• Hematuria
• Proteinuria
• Edema
• Others

Population Type:

• Pediatrics
• Adults

Route of Administration:

• Oral
• Parenteral
• Others

Treatment:

• Medication
• Statin therapy
• Omega-3 fatty acids
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin receptor blockers (ARBs)
• Diuretics
• Immunosuppressants
• Kidney Transplantation
• Others

End Users:

• Hospitals
• Specialty Clinics
• Homecare
• Others

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube